Glycomimetics SEC Filings

Form 3 Overview: The filing represents the initial statement of beneficial ownership for Jonathan McNeill, newly appointed Chief Operating Officer and President of the post-merger entity now known as Crescent Biopharma, Inc. (formerly GlycoMimetics, Inc.; ticker shown as CBIO). The triggering event is the closing of a two-step merger completed on 13 June 2025 followed by the company’s redomiciliation from Delaware to the Cayman Islands effective 16 June 2025.

Equity Position:

• 134,200 ordinary shares are beneficially owned directly via restricted stock units (RSUs). These RSUs vest 25 % on 17 Mar 2026 and 6.25 % quarterly thereafter through 17 Mar 2029, contingent on continued service.
• 402,600 stock options (right to buy ordinary shares) with a $6.16 exercise price; vest 25 % on 17 Mar 2026 with monthly vesting through 17 Mar 2029.

Corporate Actions Highlighted:

• The transaction combined GlycoMimetics with Crescent Biopharma via two successive subsidiary mergers, resulting in Crescent Biopharma Operating Company, LLC as the surviving operating entity.
• Immediately after the merger, the parent company adopted the Crescent Biopharma, Inc. name.
• All outstanding Delaware-based equity awards seamlessly converted into equivalent Cayman Islands instruments under identical terms.

Governance Note: McNeill’s simultaneous roles as COO and President and his direct ownership stake align management incentives with shareholder interests. A power of attorney is on file, executed by attorney-in-fact Barbara Bispham, and the Form 3 was signed on 23 June 2025.

Form 3 highlights for GlycoMimetics Inc. (now Crescent Biopharma, Inc.)

On 06/23/2025 Fairmount Funds Management LLC and its affiliated investment vehicle Fairmount Healthcare Fund II L.P. filed an Initial Statement of Beneficial Ownership (Form 3) following the closing of a complex restructuring that included (i) a two-step merger between GlycoMimetics, Inc. and privately held Crescent Biopharma, Inc. completed on 06/13/2025 and (ii) a redomicile from Delaware to the Cayman Islands effective 06/16/2025.

Equity position disclosed

• Ordinary shares: 1,387,866 shares held indirectly by Fairmount Healthcare Fund II L.P.
• Series A Non-Voting Convertible Preferred Shares: 2,890 shares, convertible into 2,890,000 ordinary shares; no expiration date and subject to a beneficial-ownership cap.
• Pre-funded warrants: 1,636,706 warrants exercisable at $0.001 per share; no expiration date but capped at 9.99% ownership upon exercise.

Aggregating the ordinary shares, the preferred share conversion amount, and underlying warrant shares, Fairmount controls or can acquire up to approximately 5.9 million ordinary shares. This exceeds the 10 % ownership threshold, and the filing confirms the filer’s dual status as both a director by deputization (through Peter Harwin) and a 10 % beneficial owner.

Key structural details

• Each Crescent common share exchanged for 0.1445 ordinary shares of the issuer.
• Each share of Crescent Seed Preferred exchanged for 0.0001445 Series A Preferred Shares.
• All Crescent pre-funded warrants exchanged 1:1 (0.1445 ratio applied) into issuer pre-funded warrants.

No cash consideration, valuation data, or earnings metrics are provided in the Form 3. The filing mainly establishes the post-merger and post-redomicile capital structure and confirms Fairmount’s governance role and sizable equity stake.

Nuveen Quality Municipal Income Fund (NAD) submitted a LIVE Form NPORT-P monthly portfolio report to the SEC; however, the excerpt provided is largely a blank template with placeholder rows and no populated financial data.

The filing confirms only that it is not the Fund’s final submission (Item A.4 shows “No”) and that non-cash collateral may have been accepted in securities-lending transactions (Item B.4.b offers a Yes/No choice but no selection is shown). Key quantitative sections—assets, liabilities, risk metrics, monthly returns, and share-flow information—contain no figures. As such, investors receive no insight into portfolio composition, leverage, risk, or recent performance from this excerpt.

Form 3 overview: Director Susan Moran filed an initial beneficial ownership report following GlycoMimetics, Inc.’s transformative merger with Crescent Biopharma and immediate re-branding to Crescent Biopharma, Inc. ("Issuer"). The filing date of record is 13 Jun 2025.

Equity position disclosed: Moran holds a single derivative security—an option to purchase 20,164 ordinary shares at an exercise price of $6.16, expiring 11 Dec 2034. Of these, 3,360 options are fully vested; the remaining 16,804 vest in equal monthly tranches through 11 Dec 2027, contingent on continued board service.

Corporate actions driving the filing:

• Two-step merger (First Merger & Second Merger) completed 13 Jun 2025: GlycoMimetics created and merged two wholly-owned subsidiaries with Crescent Biopharma, leaving Crescent as a wholly-owned operating subsidiary.
• Post-merger, GlycoMimetics adopted the Crescent Biopharma name.
• Re-domicile: On 16 Jun 2025 the Issuer converted from a Delaware corporation to a Cayman Islands exempted company. All outstanding U.S. equity awards were automatically converted into rights over Cayman ordinary shares on identical terms.

Implications for investors: The Form 3 itself does not alter outstanding share count or economics, but it formalises insider ownership under the new capital structure, confirms option continuity across the merger and re-domicile, and signals that governance reporting has transitioned to the Cayman entity.

Schedule 13G filing: Venrock Healthcare Capital Partners III, L.P. and affiliated funds, together with individuals Nimish Shah and Bong Y. Koh (collectively, the “Reporting Persons”), disclosed ownership of 1,391,196 ordinary shares of Crescent Biopharma, Inc. (CUSIP 38000Q201) as of 13 June 2025. This holding represents 9.9 % of the company’s outstanding shares. The Reporting Persons hold shared voting and shared dispositive power over the entire position; no sole voting or dispositive power is reported. All entities are Delaware-organized, while Shah and Koh are U.S. citizens. The filing was made pursuant to Rule 13d-1(c), suggesting a passive investment stance. No sale or purchase transactions, price data, or changes from prior ownership levels were disclosed.